Published On: July 4, 2023Categories: News, Podcast

Professor Martin Metz joins Professor Marcus Maurer to answer an audience proposed question focusing on what will guide physicians in the recommendations for individual patients to identify the most beneficial treatment option to treat chronic spontaneous and inducible urticaria. Both experts delve into the current treatment options available, and exciting treatments that are currently in clinical trials.

Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.

Utilise the following external links to access additional resources relating to the topics discussed in this episode: Dupilumab in CSURemibrutinib in CSUBruton’s tyrosine kinase inhibition—An emerging therapeutic strategy in immune-mediated dermatological conditionsAn open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticariaBarzolvolimab in mast cell depletionChronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advancesChronic urticaria and the pathogenic role of mast cells and Urticaria (an overview).

Read more news regarding urticaria

  • News

    April 15, 2024

    With 85 episodes, our podcast all Things Urticaria has reached 30.000 downloads! Listen to all episodes here: SPOTIFY APPLE PODCAST

  • New centers,News

    April 12, 2024

    On March 28, Marcus Mauer had the great privilege to perform a triple re-audit for  UCARE, ACARE and ADCARE  at the Peking University First Hospital Center in Beijing, China. [...]

  • New centers,News

    April 12, 2024

    A very warm welcome to our newest UCARE (and ACARE) Center in Spain: Hospital General Universitario Gregorio Marañón Allergy Department Head: Dr. Ana Entrala Bueso Deputy: Dr. María Luisa Baeza [...]